Zydus Lifesciences’ in-licensed pembrolizumab biosimilar met the primary endpoint in a pivotal PK study, paving the way for a near-term USFDA filing and entry into the North American market.
Zydus Lifesciences’ in-licensed pembrolizumab biosimilar met the primary endpoint in a pivotal PK study, paving the way for a near-term USFDA filing and entry into the North American market.